Lutathera®, a radioligand therapy by Novartis, showed significant progression-free survival rates in initial stage advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

This article summarized the latest R&D progress of Brentuximab Vedotin, the Mechanism of Action for Brentuximab Vedotin, and the drug target R&D trends for Brentuximab Vedotin.

Proteases are enzymes that play a crucial role in the human body by breaking down proteins into smaller peptides or amino acids.

Arformoterol Tartrate is a small molecule drug that targets the β2-adrenergic receptor. It is primarily used in the treatment of various respiratory diseases.

Shanghai Henlius Biotech, Inc. has made a public announcement that the NMPA has given approval to the NDA for an innovative fresh indication of HANSIZHUANG (serplulimab injection).

This article summarized the latest R&D progress of Doxepin Hydrochloride, the Mechanism of Action for Doxepin Hydrochloride, and the drug target R&D trends for Doxepin Hydrochloride.

PRMT5 expression is associated with a poor prognosis in tumor progression and metastasis.

This article summarized the latest R&D progress of Torsemide, the Mechanism of Action for Torsemide, and the drug target R&D trends for Torsemide.

SELLAS reveals uplifting preliminary findings in Lymphoma group from SLS009 Phase 1 Increasing-Dose Study, promoting progression to Phase 2 Clinical Experiment.

This article summarized the latest R&D progress of Nabumetone, the Mechanism of Action for Nabumetone, and the drug target R&D trends for Nabumetone.

PARP1 is the most prominent member of the PARP family, accounting for 80%-90% of the enzyme activity, and is a key player in DNA damage repair.

This article summarized the latest R&D progress of Thiocolchicoside, the Mechanism of Action for Thiocolchicoside, and the drug target R&D trends for Thiocolchicoside.